NeOnc Technologies (NTHI) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NeOnc Technologies (NTHI) has outperformed Upstream Bio (UPB) over the past year, losing 46.2% versus a loss of 93.8%. NeOnc Technologies is the larger company by market cap ($90.9 million vs $87.2 million), about 1.0 times the size, while Upstream Bio is growing revenue faster (+20.4% vs -51.8%). Upstream Bio converts more of its revenue into profit, with a net margin of -5026.0% versus -155404.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | UPB |
|---|---|---|
| Share price | $3.15 | $1.59 |
| Market cap | $90.88M | $87.15M |
| 1-day change | -9.48% | -20.50% |
| YTD return | -61.91% | -94.14% |
| 1-year return | -46.25% | -93.78% |
| EPS (TTM) | $-1.95 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $39.99K | $2.85M |
| Revenue growth (YoY) | -51.82% | +20.42% |
| Net income (latest FY) | $-62.15M | $-143.44M |
| Operating margin | -145637.52% | -5618.82% |
| Net margin | -155404.38% | -5026.03% |
| 52-week high | $11.38 | $33.68 |
| 52-week low | $2.50 | $1.56 |
| Distance from 52-week high | -72.31% | -95.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +439.68% | +1245.91% |
| Average volume | 187.23K | 1.01M |
| Shares outstanding | 28.85M | 54.81M |
| Employees | 5 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTHI has outperformed UPB by 47.5 percentage points over the past year.
- Upstream Bio is more profitable, keeping -5026.0 cents of every revenue dollar as net income versus -155404.4 cents for NeOnc Technologies.
- Upstream Bio grew revenue faster in its latest fiscal year (+20.42% vs -51.82%).
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
NTHI vs UPB FAQ
Which is bigger, NeOnc Technologies or Upstream Bio?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $90.88M compared with $87.15M for Upstream Bio (UPB).
Which stock has performed better over the past year, NTHI or UPB?
NTHI returned -46.25% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.